Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT03 vs Xgeva PK Study in Healthy Males
NCT05876949Phase 1Completed
- Sponsor
- Alvotech
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DenOsteoRel in bone metastases, Giant Cell Tumor of Bone (GCTB) and hypercalcemia of malignancy (HCM) (2 arms), sponsored by Alvotech. Primary endpoints: Maximum Serum Concentration at Day 196 and Area Under the Serum Concentration-time Curve up to Time t at Day 196. Started Jul 2023; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
bone metastasesGiant Cell Tumor of Bone (GCTB)hypercalcemia of malignancy (HCM)
Beyond the preview
Go deeper on NCT05876949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876949.